ACADIA Pharmaceuticals Inc ACAD:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:00 PM EDT
17.05UNCH (UNCH)
Volume
49,175
Close
17.05quote price arrow up+0.34 (+2.03%)
Volume
1,575,656
52 week range
16.16 - 33.99
Loading...
  • Open16.84
  • Day High17.57
  • Day Low16.84
  • Prev Close16.71
  • 52 Week High33.99
  • 52 Week High Date07/18/23
  • 52 Week Low16.16
  • 52 Week Low Date04/25/24

Key Stats

  • Market Cap2.809B
  • Shares Out164.77M
  • 10 Day Average Volume1.56M
  • Dividend-
  • Dividend Yield-
  • Beta0.42
  • YTD % Change-45.54

KEY STATS

  • Open16.84
  • Day High17.57
  • Day Low16.84
  • Prev Close16.71
  • 52 Week High33.99
  • 52 Week High Date07/18/23
  • 52 Week Low16.16
  • 52 Week Low Date04/25/24
  • Market Cap2.809B
  • Shares Out164.77M
  • 10 Day Average Volume1.56M
  • Dividend-
  • Dividend Yield-
  • Beta0.42
  • YTD % Change-45.54

RATIOS/PROFITABILITY

  • EPS (TTM)-0.38
  • P/E (TTM)-45.18
  • Fwd P/E (NTM)26.52
  • EBITDA (TTM)-67.827M
  • ROE (TTM)-14.73%
  • Revenue (TTM)726.437M
  • Gross Margin (TTM)94.27%
  • Net Margin (TTM)-8.44%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/08/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On ACADIA Pharmaceuticals Inc

 

Profile

MORE
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE...
Stephen Biggar M.D., Ph.D.
Independent Chairman of the Board
Stephen Davis CPA
Chief Executive Officer, Director
Brendan Teehan
Chief Operating Officer, Executive Vice President, Head of Commercial
Mark Schneyer
Chief Financial Officer, Executive Vice President
Douglas Williamson
Executive Vice President - Research and Development
Address
12830 El Camino Real, Suite 400
San Diego, CA
92130
United States

Top Peers

SYMBOLLASTCHG%CHG
TXG
10X Genomics Inc
26.92-2.36-8.06%
GLPG
Galapagos NV
29.34+0.89+3.13%
MYGN
Myriad Genetics Inc
19.47-0.10-0.51%
GH
Guardant Health Inc
18.26+0.26+1.44%
PTCT
PTC Therapeutics Inc
34.16+2.01+6.25%